We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Novartis AG | NYSE:NVS | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -1.03 | -1.06% | 96.47 | 97.47 | 96.85 | 97.21 | 1,426,050 | 22:29:19 |
From May 2019 to May 2024
By Anthony Shevlin
Shares in Sanofi SA (SAN.FR) rose Friday after the French drug maker named Novartis AG's (NOVN.EB) pharmaceutical unit head Paul Hudson as its new chief executive.
Sanofi said Mr. Hudson will replace outgoing chief executive Olivier Brandicourt who has decided to retire. Mr. Hudson's incorporation is effective September 1.
At GMT 1055, shares in Sanofi traded 5.1% higher at EUR78.85.
"Key questions for the new CEO will be group structure--remain diversified or explore options for the consumer division--and capital allocation," said Citi analysts, who anticipated a positive market reaction.
Analysts at Bryan Garnier expect Mr. Hudson to push the drug maker to accelerate its transformation.
"We expect Paul Hudson to form with the new CFO a very dynamic and productive tandem that will convince the investment community about its strategy and present a new roadmap, hopefully by the end of the year," the bank says.
Write to Anthony Shevlin at anthony.shevlin@dowjones.com; @anthony_shevlin
(END) Dow Jones Newswires
June 07, 2019 07:29 ET (11:29 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Novartis Chart |
1 Month Novartis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
